drugset / Trial / NCT00409929

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071

NCT00409929

Phase 1 Completed 16 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and tolerability of ascending single oral doses greater than 500 mg of AEB071 in healthy subjects

Timeline

Start
2006-06
Primary completion
2006-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject sotrastaurin Small molecule Oral

Indications

No indication recorded.